RHYTHM PHARMACEUTICALS CMO Joshi Manher Receives Awards

What Happened Joshi Manher, Chief Medical Officer of Rhythm Pharmaceuticals (RYTM), received two equity awards on August 17, 2026: a grant of 50,000 stock options (derivative) and 25,000 restricted stock units (RSUs). Both awards were reported at $0.00 per share (i.e., grant awards rather than open-market purchases or sales). These are compensation grants, not sales — they do not represent a purchase of shares on the open market.

Key Details

• Transaction date: 2026-08-17; filing date: 2026-08-18 (reported the next day).
• Reported price: $0.00 for both the option and RSU awards (code A = award/grant).
• Option grant: 50,000 shares (derivative); RSU grant: 25,000 shares (derivative).
• Shares owned after the transaction: Not disclosed in the provided filing excerpt.
• Footnotes / vesting:
  • F1 (options): 25% of the options vest on the first anniversary of the grant; then 6.25% of the total options vest upon each successive three-month period of service thereafter.
  • F2 (RSUs): 25% of the RSUs vest on September 1 of each year 2027–2030, fully vesting on September 1, 2030, subject to continued service.
  • F3: The RSUs have no expiration date.
• No indication in the filing that this was an exercise, sale, gift, or part of a 10b5-1 plan.

Context

• Stock options become valuable only after they vest and are exercised; RSUs convert to shares upon vesting. Both are common executive compensation tools and do not by themselves signal buying or selling intent in the market.
• Because these are awards, there was no immediate cash transaction reported.